Germany’s Merck KGaA has announced a major acquisition agreement to buy U.S.-based life sciences company Bio-Techne Corp (NASDAQ:TECH) in a deal valued at approximately $11.3 billion, marking one of the pharmaceutical and life-sciences sector’s most significant transactions of the year.
Under the terms of the agreement, Merck will pay $73 per share in cash, representing a premium of around 24% to 36% over Bio-Techne’s recent trading averages, depending on the benchmark period used. Following the announcement, Bio-Techne shares rose sharply in premarket trading, reflecting investor approval of the offer.
Strategic Rationale Behind the Acquisition
The acquisition is designed to strengthen Merck’s life sciences division, particularly in areas such as:
- Drug discovery tools
- Diagnostic technologies
- Biopharmaceutical manufacturing support
- Research reagents, proteins, and antibodies
Bio-Techne is known for supplying critical laboratory tools and technologies used widely by researchers and pharmaceutical developers, making it a strong strategic fit for Merck’s expanding portfolio.
Financing and Structure
Merck plans to fund the transaction through a combination of:
- Existing cash reserves
- Newly issued debt
The deal remains subject to regulatory approvals and Bio-Techne shareholder consent, with completion expected in late 2026 or early 2027.
Strategic Context for Merck
This acquisition is:
- One of Merck’s largest in recent years
- Its biggest deal since the $17 billion purchase of Sigma-Aldrich in 2015
- The first major transaction under new CEO Kai Beckmann
The move signals Merck’s renewed push to expand its global leadership in life sciences and research infrastructure, an increasingly competitive and consolidating sector.
Market Reaction and Outlook
Investors reacted positively, with Bio-Techne shares jumping significantly after the announcement. Analysts expect the deal to enhance Merck’s scale in research tools and potentially generate cost synergies estimated at around €140 million annually after integration.
However, as with all large pharmaceutical acquisitions, execution risk remains tied to regulatory approval timelines and successful integration of operations.